Nalaganje...
Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system
BACKGROUND: Infliximab (Remicade), a chimeric monoclonal antibody against human TNFα, will inevitably face competition from biosimilar products, because of its effectiveness in autoimmune diseases and rapidly increasing market demand. According to guidelines for biosimilar development, the “biosimil...
Shranjeno v:
| izdano v: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6420106/ https://ncbi.nlm.nih.gov/pubmed/30880912 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S170913 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|